Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?
JP Gisbert, M Chaparro - Journal of Clinical Medicine, 2021 - mdpi.com
Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
Inflammatory bowel disease (IBD) management has changed dramatically over the past 20
years, after the introduction of targeted biological therapies. However, the impact of these …
years, after the introduction of targeted biological therapies. However, the impact of these …
Effectiveness and safety of vedolizumab in inflammatory bowel disease: a comprehensive meta-analysis of observational studies
FS Macaluso, M Ventimiglia… - Journal of Crohn's and …, 2023 - academic.oup.com
Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …
Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the Eneida registry
Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF)
agent is not known. The aim of this study was to analyze the effectiveness and safety of …
agent is not known. The aim of this study was to analyze the effectiveness and safety of …
Artemisinin ameliorates intestinal inflammation by skewing macrophages to the M2 phenotype and inhibiting epithelial–mesenchymal transition
M Huai, J Zeng, W Ge - International Immunopharmacology, 2021 - Elsevier
Background Inflammatory bowel disease (IBD) is a self-destructive intestinal disease whose
etiology is unclear but complex and the effective treatment is deficient. Increasing evidences …
etiology is unclear but complex and the effective treatment is deficient. Increasing evidences …
Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD …
C Kapizioni, R Desoki, D Lam… - Journal of Crohn's …, 2024 - academic.oup.com
Abstract Background and Aims This study compares the effectiveness of different biologic
therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world …
therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world …
Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish …
S Rundquist, MC Sachs, C Eriksson… - Alimentary …, 2021 - Wiley Online Library
Background Comparisons of second‐line anti‐tumour necrosis factor (TNF) agents and
vedolizumab are sparse. Aim To evaluate the effectiveness of anti‐TNF agents compared to …
vedolizumab are sparse. Aim To evaluate the effectiveness of anti‐TNF agents compared to …
Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience
FS Macaluso, M Maida, M Grova… - Therapeutic …, 2021 - journals.sagepub.com
During past years, the increasing knowledge of molecular mechanisms of inflammatory
bowel disease (IBD) have led to the development of several targeted biological therapies …
bowel disease (IBD) have led to the development of several targeted biological therapies …
Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis
E Zhuleku, D Wirth, R Nissinen… - Therapeutic …, 2024 - journals.sagepub.com
Background: Biologic agents have demonstrated efficacy in treating ulcerative colitis (UC);
however, treatment failure to tumor necrosis factor inhibitors (TNFi) is common in the real …
however, treatment failure to tumor necrosis factor inhibitors (TNFi) is common in the real …
Ustekinumab for treating ulcerative colitis: an expert opinion
Introduction Biologic agents have revolutionized the therapeutic management of ulcerative
colitis. Anti-tumor necrosis factor agents were the first biologic drugs used to induce and …
colitis. Anti-tumor necrosis factor agents were the first biologic drugs used to induce and …